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Background: The Alere point-of-care (POC) Pima™ CD4 analyzer allows for decentralized testing and expansion to
testing antiretroviral therapy (ART) eligibility. A consortium conducted a pooled multi-data technical performance
analysis of the Pima CD4.
Methods: Primary data (11,803 paired observations) comprised 22 independent studies between 2009–2012 from
the Caribbean, Asia, Sub-Saharan Africa, USA and Europe, using 6 laboratory-based reference technologies. Data
were analyzed as categorical (including binary) and numerical (absolute) observations using a bivariate and/or
univariate random effects model when appropriate.
Results: At a median reference CD4 of 383 cells/μl the mean Pima CD4 bias is -23 cells/μl (average bias across all CD4
ranges is 10 % for venous and 15 % for capillary testing). Sensitivity of the Pima CD4 is 93 % (95 % confidence interval
[CI] 91.4 % - 94.9 %) at 350 cells/μl and 96 % (CI 95.2 % - 96.9 %) at 500 cells/μl, with no significant difference between
venous and capillary testing. Sensitivity reduced to 86 % (CI 82 % - 89 %) at 100 cells/μl (for Cryptococcal antigen (CrAg)
screening), with a significant difference between venous (88 %, CI: 85 % - 91 %) and capillary (79 %, CI: 73 % - 84 %)
testing. Total CD4 misclassification is 2.3 % cases at 100 cells/μl, 11.0 % at 350 cells/μl and 9.5 % at 500 cells/μl, due to
higher false positive rates which resulted in more patients identified for treatment. This increased by 1.2 %, 2.8 % and
1.8 %, respectively, for capillary testing. There was no difference in Pima CD4 misclassification between the meta-analysis
data and a population subset of HIV+ ART naïve individuals, nor in misclassification among operator cadres. The Pima
CD4 was most similar to Beckman Coulter PanLeucogated CD4, Becton Dickinson FACSCalibur and FACSCount, and less
similar to Partec CyFlow reference technologies.
Conclusions: The Pima CD4 may be recommended using venous-derived specimens for screening (100 cells/μl)
for reflex CrAg screening and for HIV ART eligibility at 350 cells/μl and 500 cells/μl thresholds using both capillary
and venous derived specimens. These meta-analysis findings add to the knowledge of acceptance criteria of the
Pima CD4 and future POC tests, but implementation and impact will require full costing analysis.
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Globally, 34 million individuals are infected with HIV,
and currently nearly 14 million worldwide are receiving
antiretroviral therapy (ART) [1]. The number of add-
itional HIV-positive patients eligible for ART has in-
creased a further 12 million for a total of 25.9 million
eligible patients. The treatment gap, however, remains* Correspondence: lesley.scott@nhls.ac.za
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changes are required to improve the number of individ-
uals initiating treatment [2]. Many HIV-positive patients,
however, do not have reliable access to required diagnos-
tic laboratory tests, including CD4 enumeration since
CD4 testing is often only available in regional laborator-
ies. This longer turnaround time on results impacts on
patient retention in care [3–5]. It should also be noted
that the need for such testing and the thresholds of CD4
counts that clinicians deem relevant for treatment
initiation are moving targets [6]. In addition to ARTcle distributed under the terms of the Creative Commons Attribution License
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Scott et al. BMC Medicine  (2015) 13:168 Page 2 of 14initiation, CD4 counts are also being used as a screening
tool for reflex testing to screen for and prevent Crypto-
coccal meningitis in patients with a CD4 count <100
cells/μl [2]. There is therefore a critical need to expand
access to HIV diagnostic testing services.
Generally, method comparison studies of new tech-
nologies compared to the reference technologies are per-
formed to address these critical issues. The Pima CD4
(Alere, Jena, Germany) was one of the first commercially
available point-of-care (POC) CD4 technologies. It en-
tered the market in 2009 and provides a CD4 result in
20 min, is very easy to use, requires no refrigeration of
reagents or controls, and can be operated with battery
power [7]. Over many years the ART initiation target in
many low- and middle-income countries has been CD4
counts <200 cells/μl, expanded more recently to include
thresholds of <350 cells/μl [8] and was further raised
to <500 cells/μl in the WHO 2013 guidelines [2]. The
selection of accurate and affordable POC CD4 technolo-
gies that can increase access to testing remains necessary
in many regions for attaining ambitious 2015 treatment
initiation goals [9]. Implementation of POC CD4 testing
in primary health care facilities has been shown to re-
duce test turnaround time, reduce pre-ART loss to
follow-up, and increase prompt ART initiation [10, 11],
yet implementing an inaccurate and imprecise CD4 test-
ing platform would be costly to patients and national
programs.
Despite the more than 50 technical evaluation studies
of the Pima CD4 being performed in dozens of coun-
tries, this has not been reported in a consolidated format
nor has the venous versus capillary blood detection
debate reached a conclusion. Each study adds to the
breadth of knowledge, but there is little guidance on ac-
ceptable evaluation criteria specifically for CD4 testing
technologies [12]. We sought to conduct a pooled data
meta-analysis to address these issues and generate guid-
ance for national programs and future CD4 test devel-
opers. The objectives of this pooled multi-data analysis
were to summarize the performance of the Alere
Pima POC CD4 technology at three clinical thresh-
olds [100 cells/μl (to identify patients in need of reflex test-
ing for prevention of Cryptococcal meningitis); 350 cells/μl
(to identify patients eligible for ART according to the
2010 WHO guidelines) and 500 cells/μl (to identify
patients eligible for ART according to the 2013 WHO
guidelines)] compared with several laboratory-based
reference technologies and across global regions.
Methods
Study selection and data pooling
An initiative between researchers at the University of the
Witwatersrand, the Clinton Health Access Initiative
(CHAI), the World Health Organization (WHO) and theUS Centers for Disease Control and Prevention (CDC)
led to the formation of a Pima CD4 consortium com-
prising 34 individuals. Studies were either undergoing
publication, already published evaluations on the Pima
CD4, or were in-country regulatory evaluations of the
technology and were willing to supply their study data.
A PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) analysis was performed
with a modified checklist since this “meta-analysis” in-
volved re-analysis of observation pairs from groups will-
ing to supply their data [13]. The STARSD (Standards
for Reporting Studies of Diagnostic Accuracy) analysis
criteria were followed where applicable to method com-
parison of CD4 paired observations [14]. Data sets from
each group were received in MS Excel format and
merged into one worksheet containing the following
minimum set of variables: observation pair number,
country, Pima CD4 count (cells/μl), reference CD4 count
(cells/μl) and type, specimen type (capillary or venous
derived) and year in which observations were collected.
The “predicate”, “in-country”, “gold standard”, “standard”
and “reference” CD4 technology terminology often applied
to CD4 enumeration evaluation studies are collectively
referred to in this article as reference CD4 technology.
These included the Beckman Coulter PanLeucogated CD4
(Beckman Coulter, Miami, FL, USA), the FACSCount,
FACSCalibur and FACScan (Becton Dickinson Biosciences,
San Jose, CA, USA), the CyFlow (Partec, Munster,
Germany) and the Guava EasyCD4 (Merck Millipore,
Billerica, MA).
Statistical analysis
Analyses were performed using MS Excel, Stata 13
(StataCorp, College Station, TX) and SAS (SAS Version
9.2,SAS Institute Inc). Data were analyzed as categorical
(including binary) and numerical (absolute) observations




A PRISMA flow diagram (Fig. 1) outlines 34 studies suit-
able for inclusion in the meta-analysis, and 22 research
studies agreeing to participate in this meta-analysis and
providing consent for primary data inclusion. These con-
sisted of 10 published studies, 3 studies currently under
publication submission and 9 in-country (regulatory)
studies. All of these studies investigated the performance
of the Pima CD4, either in the laboratory or in health
care facilities. Figure 2 illustrates that among the six ref-
erence technologies employed across all studies the
FACSCount was the predominant reference comparator
used in 41 % of the observation pairs. Observations were
collected from five global regions between 2009 and
Table 1 Description of data analysis
(a) Catagorical data analysis
Data format Methods
The number (proportion) of CD4 observations in the following CD4
categories: <100 cells/μl; 100 – 350 cells/μl; 350–500 cells/μl and
>500 cells/μl was determined for both Pima CD4 and reference
methods. The data were further divided into the type of specimen
(venous or capillary) tested on the Pima CD4
Significance (p ≤0.05) between categories was determined using the
proportions test.
The Pima CD4 and reference CD4 observations were also converted
to binary (0 = above the specified threshold and 1 = below the
threshold). The observation pairs were also sorted by specimen type,
comparator reference technology and year when observations were
collected.
The false positive, false negative, sensitivity (ability to correctly identify
patients requiring treatment) and specificity (ability to correctly identify
patients not requiring treatment) were calculated for the three clinical
thresholds of the entire dataset. The total misclassification rate
(percentage) was calculated as the addition of false positive rate and
false negative rate. The upward (percentage of patients requiring
treatment incorrectly identified by the Pima CD4 as above the threshold)
and downward (percentage of patients not requiring treatment incorrectly
identified by the Pima CD4 as below the threshold) misclassification rates
were calculated. The Q-statistic was calculated [35] to quantify and account
for the presence of any study heterogeneity due to differences in sample
size, study quality, study designs, and/or data collection methods. A
bivariate and/or univariate random effects model was applied using
METANDI commands in STATA 13.
(b) Numerical data analysis
Methods applied (where applicable, 95 % confidence intervals (CI)
were reported)
Description
Data description. The CD4 count paired observations were described by mean
(using random effects models), median and standard deviation (SD).
The agreement between the Pima CD4 and reference technology
was measured using the Bland-Altman (bias [or mean difference]
and SD of the bias) [23],
The Bland-Altman measures the difference between observation pairs (a-b),
where method ‘a’ is the Pima CD4. The mean paired difference
(the bias or accuracy) and SD of this bias (precision) were determined.
A zero mean difference implies good accuracy between reference and
Pima CD4 and a small SD of the bias implies good precision (low variability).
The accuracy and precision are visually represented on a modified
Bland-Altman difference plot with the paired difference on the vertical
axis and the absolute CD4 count of the reference on the horizontal axis.
The agreement between the Pima CD4 and reference technology
was also measured using the percentage similarity (mean, SD and
coefficient of variation [CV]) [24],
The percentage similarity is calculated as the average between the
reference and Pima CD4 technology represented as a percentage of
the reference technology: [([a + b]/2) /b] × 100, where ‘b’ is the
reference method. Observation pairs with the same value will be
100 % similar (accurate) and observation pairs where the Pima CD4
is greater than the reference will be > 100 %, and conversely <100 %
if Pima CD4 has a value smaller than the reference. The amount of
variability (precision) is represented by the percentage similarity SD
and overall agreement by the percentage similarity CV.
The agreement between the Pima CD4 and reference technology
was also measured using the percent difference (bias, SD) [25]
The percentage difference is calculated as (a-b)/b (or the average
between ‘a’ and ‘b’) × 100 % [25]. Observation pairs with the same
value will have no difference and therefore low percent difference,
as the percentage difference method is more relative than absolute
difference over the range of data.
The strength of the agreement (accuracy and precision) was measured
by the concordance correlation (Pc) between the Pima CD4 and
reference technologies [17, 36]
The formula applied is pc (concordance correlation) = p (Pearson
correlation [measure of precision]) x Cb (bias correction factor
[measure of accuracy]) [17, 36]. The value of pc (strength of agreement)
is suggested as: <0.9 (poor); 0.90-0.95 (moderate); 0.95 – 0.99 (substantial);
>0.99 (almost perfect) [17, 36].
(c) Subset analysis
Description of subset Methods applied
Sample size in method comparison: Few CD4 method comparison
studies’ sample sizes are based on statistical criteria, but rather
constrained by costs. This pooled meta-analysis data set afforded the
ability to investigate potential impact of sample size on statistical
outcomes. An analysis was therefore performed on a subset of data
from the comparison between the Pima CD4 and FACSCount of
venous derived specimens, as this was the largest subset of paired
observations from a single reference and Pima CD4 comparison.
Once the data pairs were entered in MS Excel, random sample numbers
(between 1 and 3,486) and irrespective of CD4 category were generated
for each CD4 observation pair. This would ensure selection of sample
sizes would be independent of the CD4 count and range of CD4 count.
The misclassification and agreement analysis was then performed in
STATA for sample sizes ranging from 50 to 4,000. The bias, SD of the bias,
percentage similarity mean and SD, total misclassification, sensitivity and
concordance correlation were all plotted against sample size to determine
the impact of sample size on method comparison parameters.
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Table 1 Description of data analysis (Continued)
Performance of the Pima CD4 compared to various reference
technologies.
The data were sorted based on the reference CD4 method comparator
performed in comparison to the Pima CD4, irrespective of study, region
or year when the study was performed. The data selection, however,
took into account the outcome of the analysis performed in (c) on
sample size. Categorical and numerical statistical analyses were applied
and results visualized in scatter plots and bar charts.
Performance of the Pima CD4 by different cadre of staff A subset of 3,751 paired observations was evaluated for total
misclassification rates based on different healthcare worker cadres
of Pima CD4 operators. This subset was from 11 studies that provided
such information with their data. Three cadres were defined: laboratory
technician/technologist (includes scientists); laboratory assistant
(a lower level of training than technicians) and clinical staff (includes
nurses and lay counselors).
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ies. Overall 69 % of the observations were obtained from
studies conducted in sub-Saharan Africa and 47 % of ob-
servations were obtained from studies performed in
2011. The distribution plot in Fig. 3 illustrates that the
observation pairs have a broad range of CD4 counts
from 1 cell/μl to 2,580 cells/μl as reported by the Pima
CD4, with a median CD4 count of 363 cells/μl. The
median CD4 count for all reference technologies was
383 cells/μl. Of the total number of observations, 65 %
were tested by Pima CD4 using venous-derived blood
specimens, with a median CD4 count of 373 cells/μl.
The median CD4 count of the Pima CD4 using
capillary-derived specimens was 342 cells/μl, and studiesFig. 1 A PRISMA flow diagram of study identification and selectionperformed in 2009 had a lower median CD4 count
(290 cells/μl) generated from the Pima CD4 than reference
technologies (352 cells/μl) or Pima CD4 median results
generated in 2010 (327 cells/μl) compared to reference
technologies (357 cells/μl). This may indicate changes or
improvements in the Pima CD4 technology over time.
Categorical data analysis
The percentage contribution of observations in the four
CD4 categories (<100 cells/μl; 100 – 350 cells/μl;
350–500 cells/μl and >500 cells/μl) as determined by
the Pima CD4 and reference technologies found the
Pima CD4 had more observations (48.2 %) with CD4
counts <350 cells/μl than reference technologies
(44.0 %). In addition, more observations had CD4
counts <350 cells/μl from capillary derived (51 %) than
venous derived (46 %) specimens. The proportion test
indicated a significant difference (p < 0.001) between the
Pima CD4 and reference technologies in the overall
numbers of observations in all categories except the 350–
500 cells/μl category (p = 0.243). This was similarly found
among capillary derived specimens. Venous derived
specimens showed no significant difference in the 0–
100 cells/μl (p = 0.148) and 350–500 cells/μl (p = 1.06)
category assignment by the Pima CD4 compared to refer-
ence technologies.
A subset of 584 paired observations from two studies
[15, 16], that tested the performance of the Pima CD4
with specimens from HIV treatment-naïve patients, was
analyzed to ensure that the results found in this pooled
data meta-analysis (n = 11,803) can be applied to this
critical population. This would also be useful to de-
termine if changes in clinical thresholds for ART eli-
gibility criteria (350 cells/μl clinical change [17] to
500 cells/μl [2]) using the Pima CD4 would differ
from the above analysis. The percentage difference
for naïve and meta-analysis observation pairs showed
little difference: <100 cells/μl (1 % versus 0.6 %); 100–
350 cells/μl (4 % versus 3.6 %); 350–500 cells/μl (−2 %
versus 0 %) and >500 cells/μl (−3 % versus −4 %). The
Fig. 2 Tabulation of study characteristics and observations summarized in pie charts after sorting by (a) comparator reference technologies;
(b) geographic location of collected observations; (c) year in which observations reported
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ence CD4 technologies overall and in each CD4 category
in a subset of HIV-positive treatment-naive patients.
The overall sensitivity of Pima CD4 compared to all
reference technologies at all clinical thresholds analyzed
was >86 %, and improves at higher CD4 cell counts with
sensitivities above 93 % at the two ART initiation thresh-
olds of 350 cells/μl and 500 cells/μl (Table 2). The 95 %
confidence intervals for sensitivity at the 350 cells/μl and
500 cells/μl clinical thresholds overlapped between
venous and capillary derived specimens, showing thisFig. 3 Distribution of CD4 count results generated by the Pima across all t
axis is increasing CD4 count. The number of studies from different geograp
the plot. Sub-SA Sub-Saharan Africatechnology has similar performance on venous or capil-
lary derived specimens for identifying patients below
these two clinical thresholds. The overall specificity
of the Pima CD4 compared to reference technology
was >78 % across the three clinical thresholds measured
with the lowest specificity observed at the higher CD4
count threshold of 500 cells/μl. The latter comprised
15.5 % of the total number of observations with Pima
CD4 count values close to this threshold.
The overall sensitivity of the Pima CD4 at 100 cells/μl
compared to reference technologies was less (86 %) thanhe studies. The vertical axis is number of specimens and the horizontal
hic regions with various median CD4 counts is shown in textboxes on
Table 2 Categorical meta-analysis summary including random effects modeling
Overall Venous Capillary
n = 11,803 n = 7,648 n = 4155
Reference Technology
Mean (absolute range) 428 (402–453) 436 (418–474) 411 (384–437)
Median (IQR) 383 (249–555) 390 (254–565) 371 (241–537)
Pima
Mean (absolute range) 404 (373–425) 416 (388–444) 382 (351–412)
Median (IQR) 363 (234–524) 373 (242–534) 342 (221–507)
Misclassification
100 cells/μl
False positive 1.4 % (0.9 % - 2.0 %) 1.1 % (0.9 % - 1.5 %) 2.1 % (1.3 % - 3.3 %)
False negative 1.0 % (0.7 % - 1.4 %) 0.8 % (0.6 % - 1.0 %) 1.6 % (1.1 % - 2.4 %)
Total misclassification 2.3 % (1.7 % - 3.1 %) 1.8 % (1.5 % - 2.2 %) 3.5 % (2.4 % - 5.0 %)
Upward misclassification 1.5 % (1.0 % - 2.2 %) 1.2 % (0.9 % - 1.6 %) 2.2 % (1.3 % - 3.6 %)
Downward misclassification 14.3 % (11.2 % - 18.1 %) 11.9 % (9.1 % - 15.3 %) 21.0 % (16.1 % - 27.0 %)
350 cells/μl
False positive 7.5 % (5.9 % - 9.4 %) 6.3 % (4.6 % - 8.6 %) 9.3 % (7.3 % - 11.7 %)
False negative 2.9 % (2.2 % - 3.8 %) 2.3 % (1.7 % - 3.2 %) 3.9 % (2.8 % - 5.3 %)
Total misclassification 11.0 % (9.6 % - 12.5 %) 9.2 % (7.5 % - 11.1 %) 13.8 % (12.1 % - 15.8 %)
Upward misclassification 6.7 % (5.1 % - 8.6 %) 5.7 % (4.1 % - 7.9 %) 8.2 % (5.9 % - 11.2 %)
Downward misclassification 13.7 % (10.9 % - 17.2 %) 10.9 % (8.0 % - 14.6 %) 17.9 % (14.1 % - 22.5 %)
Cadre of staff analysis at 350 cells/ul
Clinical n = 1133, 12.0 % (4.7 % - 14.9 %) n = 510, 11.5 % (7.2 % - 17.8 %) n = 623, 12 % (9.3 % - 15.3 %)
Lab Assistant n = 558, 12.1 % (9.1 % - 15.9 %) n = 254, 6.6 % (2.2 % - 17.9 %) n = 304, 15 % (6.3 % - 31.9 %)
Lab Technologist/scientist n = 2060, 9.2 % (7.1 % - 11.9 %) n = 1850, 8.3 % (6.5 % - 10.7 %) n = 210, 13 % (7.3 % - 22.1 %)
500 cells/μl
False positive 6.7 % (5.6 % - 8.1 %) 6.3 % (5.0 % - 7.8 %) 7.5 % (5.8 % - 9.6 %)
False negative 2.6 % (2.1 % - 3.3 %) 2.0 % (1.5 % - 2.7 %) 3.6 % (2.8 % - 4.6 %)
Total misclassification 9.5 % (8.3 % - 10.8 %) 8.3 % (7.0 % - 9.8 %) 11.3 % (9.6 % - 13.2 %)
Upward misclassification 3.9 % (3.1 % - 4.8 %) 3.1 % (2.3 % - 4.2 %) 5.0 % (3.9 % - 6.5 %)
Downward misclassification 21.8 % (18.0 % - 26.1 %) 18.7 % (14.8 % - 23.4 %) 26.3 % (20.7 % - 32.8 %)
Sensitivity
100 cells/μl 85.7 % (81.9 % - 88.8 %) 88.1 % (84.7 - 90.9 %) 79.0 % (73.0 % - 83.9 %)
350 cells/μl 93.3 % (91.4 % - 94.9 %) 94.3 % (92.1 - 95.9 %) 91.8 % (88.8 % - 94.1 %)
500 cells/μl 96.1 % (95.2 % - 96.9 %) 96.9 % (95.8 - 97.7 %) 95.0 % (93.5 % - 96.1 %)
Specificity
100 cells/μl 98.5 % (97.8 % - 99.0 %) 98.8 % (98.4 % - 99.1 %) 97.8 % (96.4 % - 98.7 %)
350 cells/μl 86.3 % (82.8 % - 89.1 %) 89.1 % (85.4 % - 92.0 %) 82.1 % (77.5 % - 85.9 %)
500 cells/μl 78.2 % (73.9 % -82.0 %) 81.3 % (76.6 % -85.2 %) 73.7 % (67.2 % -79.3 %)
Confidence intervals quoted are at 95 %
IQR interquartile range
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The Pima CD4 may, therefore, have less ability in identify-
ing all necessary patients requiring reflex CrAg testing.
There was also a significant difference in this sensitivitybetween specimens tested from venous (88 %) compared
to capillary (79 %) derived specimens, since the CIs do not
overlap. Patients, however, not requiring CrAg reflex test-
ing will be correctly identified by the Pima CD4 since the
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nologies is high (98.5 %), and there was no significant dif-
ference between type of specimen (venous or capillary).
The impact of the sensitivity and specificity of the
Pima CD4 used at the three clinical thresholds was fur-
ther investigated through the extent of total numbers of
patients who would be misclassified (false positive + false
negative rates). The total misclassification rate of Pima
CD4 was 2.3 %, 11.0 %, and 9.5 % at the 100 cells/μl,
350 cells/μl and 500 cells/μl thresholds, respectively
(Table 2). In addition, the false positivity rates were
higher across all clinical thresholds indicating that more
patients are found eligible for treatment using the Pima
CD4 than reference CD4 technology. This relationship
was the same irrespective of specimen type; however,
there was greater total misclassification with capillary
derived blood specimen testing (3.5 % ≤100 cells/μl;
13.8 % ≤350 cells/μl and 11.3 % ≤500 cells/μl) compared
to venous derived specimen testing (1.8 % ≤100 cells/μl;
9.2 % ≤350 cells/μl and 8.3 % ≤500 cells/μl).
This is similarly reflected in the downward misclassifi-
cation rates, where 14 % of patients would be identified
by the Pima CD4 as incorrectly requiring treatment at
the ART eligibility threshold of 350 cells/μl and up to
22 % at the ART eligibility threshold 500 cells/μl com-
pared to reference CD4 technology. The upward mis-
classification of Pima CD4 at the two ART initiation
clinical thresholds was less: 7 % (at 350 cells/μl) and 4 %
(at 500 cells/μl). Both upward and downward mis-
classification rates were higher among capillary derived
specimens.
A subset of the data (n = 3,751 paired observations)
was further analyzed to investigate any differences in the
Pima CD4’s performance based on cadre of operator.
Seventy percent (n = 558 laboratory assistant; n = 2,060
laboratory technician/scientist) of the tests were con-
ducted by laboratory technicians and 30 % (n = 1,133) by
clinical staff. Table 2 highlights that the total misclassifi-
cation rate at 350 cells/μl was below 13 % for laboratory
assistants, laboratory technicians and clinical staff. La-
boratory assistants performing the Pima CD4 using
venous-derived specimens had the lowest total misclassi-
fication rate (7 %), yet they also had the highest mis-
classification rate of 15 % performing the Pima CD4 on
capillary derived specimens. Clinical staff had similar
misclassification rates (12 %) using either venous or ca-
pillary derived specimens. All analyses however showed
misclassification rates with overlapping CI’s indicating
that technical performance of the Pima CD4 does not
alter when used by different cadre of operators.
Numerical data analysis
The overall mean bias (difference) of the Pima CD4 was
−23 cells/μl compared to all reference technologies(Table 3) with overlapping 95 % CI between venous and
capillary derived specimen testing. The standard devi-
ation of the overall bias (indicator of precision or vari-
ability of the mean difference) was +/− 100 cells/μl for
this set of observation pairs with a median CD4 count of
383 cells/μl. The overall mean percentage similarity
shows that the Pima CD4 had good accuracy (101 %)
compared with the reference technologies but more
variability (116 % SD) among capillary than venous
(67 % SD) derived specimens. The strength of this
agreement (concordance correlation) between the
Pima CD4 and reference technologies is also shown
to be moderate (Pc = 0.934) for venous derived specimens
and poor (Pc = 0.874) for capillary derived specimens, with
CI’s that do not overlap.
The Bland-Altman, percentage similarity and relative
percent bias methods of measuring absolute cell agree-
ment are influenced by certain CD4 count ranges:
Bland-Altman by higher CD4 counts and the percentage
similarity and relative percent bias by lower CD4 counts.
This is visualized in Fig. 4 in the scatter plots by the fun-
nel shape of the Bland-Altman and the outliers in the
percentage similarity plots. The line plot in Fig. 4 there-
fore combines all three agreement measurements by
representing their SD (amount of variability) in the four
CD4 cell range categories based on reference CD4 tech-
nology values. Using the absolute cell difference SD for
the <100 cells/μl category and the percent similarity SD
and/or the relative percent bias SD for the >100 cells/μl
categories shows that the Pima CD4 has good overall
agreement with reference CD4 technologies from venous
derived specimens, and more variability among capillary
derived specimens. The latter is more visible among the
absolute difference line plot. Table 3 summarizes this
overall agreement (accuracy and precision) from the
combined agreement measure methods at the three
clinical thresholds. Among venous derived specimens,
the cell variance ranges from 34 to 53 cells/μl and
among capillary derived specimens it ranges from 51 to
79 cells/μl. Capillary derived specimen testing however
has twice as much cell variance (73 cells/μl) than ven-
ous derived specimens (34 cells/μl) at the 100 cells/μl
clinical threshold, which is also reflected by the signifi-
cantly reduced sensitivity, 88.1 % (CI 84.7; 90.9 %) vs
79 % (CI 73.0 %; 83.9 %) (Table 2) as previously men-
tioned. The overall average percent bias of the Pima
CD4 compared to reference technologies is 10 % for
venous derived specimens and 15 % for capillary de-
rived specimens.
Performance of the Pima CD4 compared to various
reference technologies
As illustrated in the pie chart in Fig. 2, the meta-analysis
data comprised observation pairs of the Pima CD4
Table 3 Method comparison meta-analysis summary using numerical data
Overall group Venous Capillary
n = 11,803 n = 7,648 n = 4155
Reference technology
Mean (absolute range) 428 (402–453) 436 (418–474) 411 (384–437)
Median (IQR) 383 (249–555) 390 (254–565) 371 (241–537)
Pima
Mean (absolute range) 404 (373–425) 416 (388–444) 382 (351–412)
Median (IQR) 363 (234–524) 373 (242–534) 342 (221–507)
Agreement
Accuracy and Precision (cells/ul)
Mean bias (Pima - Reference) −23 −23 −24
Mean bias (CI) (−22;-25) (−21; −25) (−20; −28)
SD bias 106 93 126
Percentage similarity mean % 101 100 103
Percentage similarity SD % 87 67 116
Percentage similarity CV % 86 67 113
Percent bias (SD) >100 cells/μl n = 11037, −3.26 % (26.4) n = 7190, −3.1 % (22.5) n = 3487, −3.54 % (32.3)
Concordance correlation (Pc) 0.914 (0.911, 0.917) 0.934 (0.931, 0.937) 0.874 (0.867, 0.881)
Strength of agreement moderate moderate poor
Overall cell variance
<100 cells/ula 34 73
100-350 cesll/ulb 38 51
350-500 cells/ulb 33 57
>500 cells/ulb 53 79
Percentage bias across all rangesc 10 % 15 %
Calculated from abias SD; bpercentage similarity SD; cthe average percentage similarity >200cells/ul
CV coefficient of variation, IQR interquartile range, SD standard deviation
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ing from 1.7 % to 41 % of the data. An impact of sample
size on method comparison was therefore investigated in
a subset analysis using the Pima CD4 versus FACSCount
observation pairs. Figure 5 illustrates the changes in mis-
classification (at the 350 cells/μl threshold), sensitivity
(at the 350 cells/μl threshold), measures and strengths of
agreement with increasing sample size using the actual
clinical data but randomly selecting different sample
sizes to include in the analyses. The strength of this
agreement (concordance correlation, Pc) remained the
most constant in value at a minimum sample size of
226. Misclassification, percentage similarity SD and SD
of the absolute bias remained constant at a minimum
sample size of 329. The percentage similarity mean
remained at a constant minimum sample size of 226,
and the absolute bias at a minimum sample size of 370.
The sensitivity remained constant at the lowest sample
size of 164. Beyond these sample sizes there is little
change in the method comparison parameters and
therefore interpretation of outcomes. Taking theseconsiderations of variability in method comparison pa-
rameters into account, the range in optimal sample size
is between 164 and 370, with the average of 280. Samples
sizes <200 show the least consistency among the method
comparison parameters.
Based on this sample size analysis, reference CD4 tech-
nologies versus Pima CD4 comparisons (numeric evalu-
ation across all CD4 count ranges) that contributed >370
(maximum) paired observations (from pooled or indi-
vidual studies) were evaluated to investigate differences
in the Pima CD4 compared to the various reference
CD4 technologies. The comparisons with the required
sample size were: FACSCount (venous n = 3,486, capil-
lary n = 1,382), Beckman Coulter (venous n = 1,195,
capillary n = 1,077), FACSCalibur (venous n = 1,643, ca-
pillary n = 1,347) and CyFlow (venous n = 932, capillary
n = 0). Figure 6 visually represents the method compari-
son parameters for these evaluations in bias scatter
plots (including SD error bars) and bar charts. The
mean absolute bias plot (A) indicates the absolute cell




Fig. 4 Agreement analysis for 11,803 data paired observations between Pima CD4 and reference CD4 technology testing. Plot (a) is a modified
Bland-Altman scatter plot with vertical axis as the mean bias (Pima CD4 - reference) and the horizontal axis the absolute CD4 count of the reference
technology. The dotted lines illustrate the typical funnel shape of difference not being relative over the range in absolute CD4 counts. Plot (b) is the
percentage similarity scatter plot with vertical axis the mean percentage similarity values and horizontal axis the absolute CD4 count of the reference.
The dotted circle highlights observations pairs that are not clinically relevant outliers in this CD4 count range, but generate high percentage similarity
values due to the nature of the method comparison formula. The vertical axis of the percentage similarity plot represents values <1,000. The line plot
(c) represents the SD of the bias on the vertical axis and the percentage relative bias SD on the secondary vertical axis and the median CD4 count in
four CD4 count categories (0–100 cells/μl; 100–350 cells/μl; 350–500 cells/μl; >500 cells/μl) on the horizontal axis. The legend shows the overlay of all
three method comparison methods (Bland-Altman, percent similarity and percent bias) for specimens sorted by the specimen extraction
method (venous and capillary)
Scott et al. BMC Medicine  (2015) 13:168 Page 9 of 14technologies, ranging from 1 to 57 cells/μl difference.
The Pima CD4 has a negative bias (generates lower
values) against the FACSCount, FACSCalibur and
Beckman Coulter reference CD4 technologies, but gener-
ates higher values (positive bias) against the CyFlow. In
addition, the Pima CD4 has the lowest variability (SD of
the bias) against the Beckman Coulter (SD = 70 cells/μl)
reference technology, but this only applies to those
specimens tested by venous collection, since capillary
tested specimens in contrast generated the greatest
variability (SD = 134 cells/μl). The mean percentage
similarity plot (B) shows that the Pima CD4 is most
similar (least variable) to the FACSCalibur (%SD = 11 %
venous derived specimens; 30 % capillary derived speci-
mens), the Beckman Coulter (%SD = 11 % venous de-
rived specimens; 41 % capillary derived specimens) and
the FACSCount (%SD = 36 % venous derived specimens)reference CD4 technologies. In addition the Pima CD4 is
least similar (most variable) compared to the CyFlow
(%SD = 177 % venous derived specimens) followed by the
FACSCount (%SD = 127 % capillary derived specimens).
The latter is similarly indicated by the high percent-
age similarity CV values of the Pima CD4 compared
to the CyFlow (165 % on venous specimens) and
FACSCount (122 % on capillary specimens) as shown
in the bar chart (B). These relationships are mirrored
in the relative percent bias (difference) plot (C), which
represents only the CD4 count range of reference CD4
technology >100 cells/μl, with the least difference (and
lowest variability) between the Pima CD4 and the
Beckman Coulter (−4.8 %, SD = 16.5 %) and between the
Pima CD4 and the FACSCalibur (−10.5 %, SD = 19.5 %)
on venous derived specimens. The largest percent differ-
ence and variability is between the Pima CD4 and
Fig. 5 Line plot of method comparison parameters over a range in sample size using observation pairs from the comparisons across studies
where FACSCount was the reference CD4 technology compared to the Pima CD4 using venous derived specimen results. The vertical axis has a
limit of 100 to accommodate both absolute and percentage method comparison parameters, and the concordance correlation is represented as
a percentage. The maximum sample size illustrated is 1,000 for optimal visualization of parameters at the critical range of variability. Misclassification and
sensitivity calculations are at the 350 cells/μl threshold. A vertical dotted line illustrates the average/optimal sample size (280) taking into account the
variability of all method comparison parameters
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even greater percent bias between the Pima CD4 and
all capillary derived specimen testing, especially the
FACSCount (−1.49 %, SD = 34.8 %) and Beckman
Coulter (3.2 %, SD = 35 %). The bar chart in Fig. 6 (d) fur-
ther illustrates the strength of these agreements between
the Pima CD4 and reference CD4 technologies, and shows
that the Pima CD4 has substantial agreement (Pc >0.95)
with the FACSCount (on venous specimens) and Beckman
Coulter (on venous specimens), and moderate agreement
(Pc >0.9) with FACSCalibur (venous specimens) and
CyFlow (venous specimens) reference technologies. How-
ever, the Pima CD4 has poor agreement (Pc <0.9) with all
reference technologies when capillary specimens were
tested.
Discussion
This pooled data meta-analysis not only comprises the
largest single data set to date published on the perform-
ance of a single CD4 enumeration technology, but also
comprises observation pairs that are representative of
CD4 counts across different geographic regions, obser-
vations collected over a fairly short time period (three
years) and predominantly (69 %) from high HIV preva-
lence settings with 55 % from resource-limited settings.
There is good representation of six reference comparator
technologies that is seldom possible in a single evalu-
ation study. In addition sub-analyses were possiblecomparing the performance of the Pima CD4 on venous
and capillary derived specimens, different cadres of staff
and sub-population of HIV ART-naïve patients. The me-
dian CD4 (383 cells/μl) from the reference CD4 technol-
ogy also shows that conclusions drawn from this study
can be well applied to the important 350 cells/μl clinical
threshold for ART initiation and categorizing this large
sample size (11,803) allows for conclusions also to be ex-
trapolated to the 100 cells/μl and 500 cells/μl clinical
thresholds. This meta-analysis, therefore, provides a
unique opportunity to evaluate the Pima CD4’s technical
performance independent of influence from patient age,
immunological status, gender, pregnancy, geographic lo-
cation, HIV status, HIV subtype (by geographic location),
instrument, reagent lot, assay version, operator training
and sample size that may otherwise influence a smaller
study’s analyses.
Overall, the Pima CD4 generates lower CD4 count
values than reference technologies with the effect that
more patients’ CD4 counts are categorized <350 cells/μl
by the Pima CD4, and this is more marked among capil-
lary than venous tested specimens. In absolute cell num-
bers this equates to an average bias between the Pima
CD4 and reference technologies of −23 cells/μl with
variability in the bias (SD) across the range in CD4
counts (1-2,800 cells/μl) increasing to SD = 93 cells/μl
difference (23 % relative bias and 67 % similarity CV) for
venous derived specimens and up to SD = 126 cells/μl
Fig. 6 Scatter plots and bar charts of method comparison parameters of the Pima CD4 compared to reference CD4 technologies. Scatter plot a=Mean
cell bias (Pima – Reference) including standard deviation error bars, with the CD4 count represented on the vertical axis. The dotted line indicates 0 bias.
Scatter plot b(I) =mean percentage similarity including the % similarity SD, with the vertical axis as % similarity. The dotted line indicates 100 %. Alongside
the scatter plot is a bar chart b(II) indicating the overall % similarity CV. Scatter plot (c) = percent bias (difference) including the percent bias SD for all
observations with reference technology values >100 cells/μl, with the vertical axis as % difference. The legend indicates the sample size and the dotted
line indicates 0 % difference. Plot d is a bar chart representing the concordance correlation between the Pima CD4 and reference technologies. The grey
scale shows the strength of agreement (<0.9 = poor; 0.9-0.95 =moderate; 0.95-0.99 = substantial)
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for capillary derived specimens. The overall bias across
all CD4 ranges may be summarized as 10 % for venous
derived and 15 % for capillary derived specimens.
Some variability was noted among the reference tech-
nologies (as has been noted by others [18]), with the
outlier (higher variability, least similarity) being the Pima
CD4 compared to the CyFlow. When the Pima CD4 was
compared to the CyFlow reference technology only,
this generated a positive bias and the most variability.
This may be due to both technologies being based on
volumetric testing and using testing volumes <50 μl.
The Pima CD4 compared to the Beckman Coulter Pan-
Leucogated reference CD4 technology yielded the least
variability, but only among venous tested specimens.
This may be due to the Beckman Coulter technology
being based on counting total white cells to generate a
CD4 count and therefore differences between freshcapillary tested Pima CD4 specimens versus >1 hour
old anti-coagulated Pima CD4 and Beckman coulter
tested specimens [19]. The Pima CD4 also compared
well to the FACSCalibur and FACSCount technologies,
but for the FACSCount this was found only for venous
derived specimens. The FACSCalibur testing requires a
highly skilled operator’s input for manual gating, inter-
pretation and complex software compared to the
FACSCount and Pima CD4 which are closed with no
operator input to refine the software selection of the
CD4 positive cell cluster. The heterogeneity among the
reference technologies illustrates the importance of
selecting the most appropriate reference technology
comparator for such technical evaluations of new tech-
nologies. Furthermore, it is critical that the reference
technologies meet all quality requirements including
participation in external proficiency testing before
commencing evaluations.
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over time was also noted, and may be due to changes in
software, hardware, changes in the type and use of
lancets as well as training of operators during implemen-
tation. Operator training is key to successful implemen-
tation of new technologies. This should be considered
for future evaluations of early versions of new platforms
that may not be fully optimized, to ensure that promis-
ing products are not unduly excluded from consider-
ation for implementation. It is also important for
national HIV treatment programs wishing to implement
the Pima CD4 (or fast followers) to be aware of allow-
able differences in bias, resulting in misclassification
rates and reduced sensitivity compared to the reference
CD4 (or current “in-country”) technology, that may im-
pact treatment costs and weigh the performance and
costs with the increased patient access such a technology
will allow.
The impact of these differences between the Pima
CD4 and reference CD4 technologies was investigated
through misclassification and overall sensitivity at three
clinical thresholds, summarized in Table 4. Overall, the
misclassification by the Pima CD4 compared to refer-
ence technology is predominantly due to higher false
positive than false negative rates and therefore more pa-
tients identified for treatment using the Pima CD4. This
results in greater downward misclassification at all
thresholds, and is also reflective in the overall specificity
of the Pima CD4 of 86 % (CI 82.8 % - 89.1 %) at the 350
cells/μl ART threshold and 78.2 % (CI 73.9 % -82.0 %) at
the 500 cells/μl ART threshold with no significant differ-
ence between venous and capillary tested specimens.
The sensitivity, however, of the Pima CD4 at the 100
cells/μl is 86 % (CI 82 % - 89 %), with a significant differ-
ence between venous and capillary derived specimens.Table 4 Clinical relevance of meta-analysis findings, for venous and
Clinical questions Venous derived specime
Is Pima suitable for screening for reflex testing
of CryAg testing at the 100 cells/μl threshold?
Suitable: 88 % sensitive,
34 cells/μl, 1.8 % total m
Good specificity >97 %
Is Pima suitable for identifying patients eligible for
ART initiation at 350 cell/μl (WHO 2010 guidelines)?
Suitable: >91 % sensitive
38-51cells/μl.
Expect 9.2 % (6.3 % false
misclassification with sp
Is Pima suitable for identifying patients
eligible for ART initiation at 500 cells/μl
(WHO 2013 guidelines)? Suitable: >95 % sensitive
53-79 cells/μl
Expect 8.3 % (6.3 % false
misclassification with 81Programmatic implications are important to consider
when implementing a new testing technology, and these
increased false positive and downward misclassification
rates mean that more patients will be identified as eli-
gible for treatment. While this will lead to initial in-
creases in overall program costs, treatment is initiated
sooner with greater impact on patients’ life years saved
[3, 10, 20–22]. It is worth stressing that these implica-
tions apply across the different thresholds irrespective of
the changes in treatment guideline to the 500 cells/μl
threshold, and additional studies can now be undertaken
to determine the impact Pima CD4 could have on out-
comes and costs.
Not only does this analysis highlight some difference
in reference technologies, but also in some method com-
parison parameters. Testing a CD4 blood specimen on
the same or on a different platform or test will yield a
different CD4 count due to variability in accuracy and
precision of both the platforms and tests. Where this
variability in the CD4 count becomes important is
whether or not the variability becomes clinically relevant
and patient management is altered. It is this variability
that is investigated in method comparisons and we are
beyond the inappropriate use of correlation and linear
regression for performing such analyses with CD4
counts [23, 24] but also realize a newer approach using
concordance correlation has value in scaling the strength
of agreement between two technologies. Appropriate
methods reported in the literature for the analysis of
continuous values of CD4 counts are the difference [23],
the percentage difference [25], the percentage similarity
[24] and the ratio [26]. The latter three transform the
observation pairs into values that can be compared
between studies (even where different samples were
tested). Specific parameters from these methods are alsocapillary derived specimen testing by the Pima CD4
n testing Capillary derived specimen testing
Negative bias of
isclassification,
Not suitable: 79 % sensitivity, Negative bias of
73 cells/μl, 3.5 % total misclassification, Good
specificity >97 %
, Negative bias Suitable: >91 % sensitive, Negative bias 38-51cells/μl.
positive) total
ecificity of 89 %
Expect 13.8 % (9.3 % false positive) total
misclassification with specificity of 82 %,Will increase
treatment costs significantly more than venous
testing.
, Negative bias Suitable: >95 % sensitive, Negative bias 53-79 cells/μl
positive) total
% specificity
Expect 11 % (7.5 % false positive)total misclassification
with 74 % specificity Will increase treatment costs
significantly more than venous testing.
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versus non-acceptable performance limits, for example,
the mean bias interpreted with the confidence interval
for accuracy and standard deviation of the bias for preci-
sion, and both accuracy and precision interpreted in the
context of the median CD4 count of the observation set.
This pooled data meta-analysis also highlighted the flaws
associated with using stand-alone method comparison
parameters. The Bland-Altman mean bias is not relative
over the range of CD4 counts, especially >100 cells/μl
and the percentage similarity and relative percentage
mean bias is influenced by outliers (non-clinical) in the
<200 cells/μl range. The combination of these method
comparison parameters provides a more optimal evalu-
ation across the range of CD4 counts. Analyses such as
sensitivity, specificity and misclassification are not typ-
ical of CD4 technical evaluations, but in the context of
CD4 being used for treatment initiation or screening for
reflex testing have proved informative.
The sub-study analyses showed no difference in the
Pima CD4 performance in a subset of HIV-positive
ART-naïve individuals versus the meta-analysis findings.
This was also true for the Pima CD4 testing performed
by different cadres of operators. In addition to these
findings, the subset analysis of the impact of sample size
on method comparison parameters determined an
average optimal sample size of 280 paired observations
(n = 164 for sensitivity and n = 370 for bias calculation)
for analyzing CD4 enumeration technologies. This there-
fore may be a guide to inform future evaluation studies
for minimum sample size requirements for different
methods of comparison.
While designing and conducting technical evaluations
takes time and significant resources, it is critical to en-
sure that a technology performs comparably to reference
standards. This pooled data meta-analysis implies that
immunological population differences do not signifi-
cantly affect the performance of CD4 diagnostic tests,
especially in countries within the same geographic re-
gion. Performing a technical evaluation in every country
considering a new product would, therefore, lead to sig-
nificant delays in product approval, implementation in
health care facilities, and improving the lives of patients.
Thus, a harmonized approach could be attained with
one large evaluation across sites and pooled data.
Conclusion
This meta-analysis focused on a method comparison
using CD4 observation pairs, and no qualitative analysis
of the Pima CD4 technology itself was investigated. Im-
plementation of POC CD4 technologies will require
strengthening of decentralized health care networks, in-
cluding supply chain, quality assessment and program
monitoring. POC CD4 technologies, however, will helpachieve the bold goals set out by WHO, UNAIDS, and
other global stakeholders of initiating significantly more
patients on ART and improving patient access to quality
care. In conclusion, this meta-analysis demonstrated that
the Pima CD4 platform can generate accurate CD4
counts to be used for ART initiation in both laboratory
and non-laboratory settings used by either skilled or
non-skilled operators.
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